Argonaut Manufacturing Services has named Rick Hancock as chief executive officer, signalling the company’s next phase of growth in drug product manufacturing and global CDMO services. Hancock, who has more than 40 years of leadership experience in pharmaceutical development and CDMOs, has been a member of Argonaut’s board of directors for nine years and has played a key role in the company’s strategic evolution.

Paul Grossman, board member, said: “Rick’s expertise and track record make him a great leader for Argonaut. He brings a rare combination of industry insight and operational excellence that reinforces our commitment to deliver premium services to our clients.”

Hancock takes over direct leadership responsibility for the organisation as it continues to expand its commercial-scale operations. In October, Argonaut opened a new drug product facility at its Carlsbad, CA campus, featuring an Annex 1-compliant isolator-based filling line capable of handling vials, prefilled syringes and cartridges. The addition of this facility increases the company’s commercial manufacturing capacity fivefold.

Rick Hancock added: “Argonaut’s future is bright, and our mission remains to help clients overcome complex challenges and deliver life-changing products to patients faster. By uniting our team’s industry-leading technical mastery and customer focus with our expanded capabilities, we strengthen our ability to meet our client’s ongoing needs.”

Argonaut specialises in clinical to commercial-scale manufacturing and is designed to manage high-value biologics and active pharmaceutical ingredients with precision and agility. The company’s experienced workforce and state-of-the-art facilities allow it to support life sciences and pharmaceutical companies worldwide, including those navigating complex regulatory and supply chain requirements.

The appointment comes at a time when the global demand for CDMO services is rising, particularly for aseptic drug product manufacturing and biologics. Argonaut’s expanded Carlsbad operations provide additional flexibility for clients seeking both commercial-scale production and specialised handling for high-value compounds.

The company said Hancock’s leadership will focus on leveraging Argonaut’s technical capabilities, driving operational efficiency and ensuring rapid delivery timelines for clients’ critical products. With the new facility now operational, Argonaut is positioned to strengthen its global footprint and respond to growing needs across drug development and commercial manufacturing.